TNF-α Inhibitors and Efalizumab for the Treatment of Skin Diseases [Internet].

Background Skin diseases like psoriasis, pyoderma gangrenosum and Behcets disease are often chronic with the need for continuous treatment and follow-up. Traditional treatment like phototherapy or systemic therapy with ciclosporin, metotrexate and retinoids are not always effective or cause long-term side effects. New biological agents, which target pathologic T cell activity, have been developed. This report deals with the biological agents tumour necrosis factor alpha (TNF-alpha) inhibitors (infliximab (Remicade®), adalimumab (Humira®), etanercept (Enbrel®) and efalizumab (Raptiva®) which is a T cell modulator.

http://ift.tt/2CSMWoh